Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Company Deals

Novo Nordisk Partners with Vivtex on $2.1B Oral Biologics Deal – Targets Obesity and Diabetes Delivery Innovation

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Fineline Cube Feb 27, 2026
Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Fineline Cube Feb 27, 2026
Company Deals

Alphabet’s Isomorphic Labs Inks Pharma Partnerships with Eli Lilly and Novartis

Fineline Cube Jan 15, 2024

Isomorphic Labs, a drug discovery company under the umbrella of Google’s parent group Alphabet (NASDAQ:...

Company Drug

MSD’s Keytruda Gains FDA Approval for Advanced Cervical Cancer Treatment

Fineline Cube Jan 15, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has received regulatory approval from the US Food...

Company Deals

Boai NKY Medical Holdings Partners with HuaDao Biopharma for CAR-T Therapy Incubator

Fineline Cube Jan 15, 2024

Boai NKY Medical Holdings Ltd (SHE: 300109), a Chinese biotech company, has announced a strategic...

Policy / Regulatory

China’s NHSA Unveils Measures to Secure Volume-Based Procurement Supply

Fineline Cube Jan 15, 2024

The National Healthcare Security Administration (NHSA) has issued a notification outlining key measures to ensure...

Company Drug

BMS’s Mavacamten Used to Treat First Patient with Hypertrophic Cardiomyopathy in Hainan

Fineline Cube Jan 15, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced that the first patient with obstructive hypertrophic cardiomyopathy...

Company Deals

Shanghai’s EnjoSim Secures Tens of Millions in Pre-Series A Funding for Expansion

Fineline Cube Jan 15, 2024

EnjoSim, a Shanghai-based developer of microbiologic self-administration systems, has reportedly secured tens of millions of...

Company Deals

Pfizer Eyes Further ADC Expansion, Potentially in China, Says Chief Oncology Officer

Fineline Cube Jan 15, 2024

Dr. Chris Boshoff, Pfizer (NYSE: PFE)’s recently appointed chief oncology officer, disclosed in an interview...

Company Drug

CARsgen Therapeutics Gets NMPA Approval for CAR-T Therapy CT011 in Hepatocellular Carcinoma

Fineline Cube Jan 15, 2024

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced that it has received approval from...

Company Drug

Simcere Pharmaceutical Group Gets NMPA Green Light for USP1 Inhibitor SIM0501

Fineline Cube Jan 15, 2024

Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...

Company

Ant Insurance Reports 23% Surge in Health Insurance Payouts, Processing 4.69 Million Claims in 2023

Fineline Cube Jan 12, 2024

Ant Insurance, a platform integrated within Alibaba’s Alipay app, reported a 23% year-on-year increase in...

Company Deals

Myrobalan Therapeutics Secures $24 Million in Series A Funding with Strong Chinese Investor Support

Fineline Cube Jan 12, 2024

Myrobalan Therapeutics, a Massachusetts-based biotech firm, has successfully completed a $24 million Series A funding...

Company Drug

Huadong Medicine’s Relmapirazin Approval Filing Accepted by NMPA for GFR Measurement

Fineline Cube Jan 12, 2024

Huadong Medicine Co., Ltd (SHE: 000963), based in China, has announced that its market approval...

Company Medical Device

Lepu Medical Secures NMPA Approval for Innovative Coronary Intravascular Impact Waveguide Tube

Fineline Cube Jan 12, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a China-based provider of cardiovascular disease solutions,...

Company Deals

CORXEL Secures Licensing Rights for Biogen’s BIIB131 in Stroke Treatment

Fineline Cube Jan 12, 2024

Shanghai-based CORXEL, formerly known as Ji Xing Pharmaceuticals, supported by RTW Investments, has secured a...

Company

Boehringer Ingelheim Expands Greek Facility to Boost Production of Jardiance and Other Medications

Fineline Cube Jan 12, 2024

Boehringer Ingelheim (BI), headquartered in Germany, has commenced the expansion of its manufacturing facility in...

Company

Fosun Kite and Medi Cover Launch First Value-Based Payment Plan for Lymphoma Treatment

Fineline Cube Jan 12, 2024

Fosun Kite and Medi Cover, a health management and patient service platform under Sinopharm (HKG:...

Company Drug

Novo Nordisk’s IcoSema Shows Promise in Late-Stage Trial for Type 2 Diabetes Management

Fineline Cube Jan 12, 2024

Danish pharmaceutical giant Novo Nordisk (CPH: NOVO-B) has announced positive results from a late-stage trial...

Company Drug

AbbVie’s Lutikizumab Advances to Phase III for Hidradenitis Suppurativa After Positive Mid-Stage Results

Fineline Cube Jan 12, 2024

AbbVie (NYSE: ABBV) has announced the progression of lutikizumab to Phase III clinical trials following...

Company

Changchun High & New Technology to Transfer 7.42% Stake to Ex-Wife in Divorce Settlement

Fineline Cube Jan 12, 2024

Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has announced plans to transfer...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for Combined Phase Ib/II Study of BAT7104 and BAT4706

Fineline Cube Jan 12, 2024

Bio-Thera Solutions Ltd (SHA: 688177), a Chinese biopharmaceutical company, has announced that it has received...

Posts pagination

1 … 377 378 379 … 627

Recent updates

  • Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion
  • Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry
  • Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate
  • Akeso’s Manfidokimab NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis
  • Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion

Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Company Drug

Akeso’s Manfidokimab NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.